Neoplasms

Digestive System Diseases

All Conditions

Barrett Esophagus

Precancerous Conditions

Esophageal Diseases

Gastrointestinal Diseases

All Drugs and Chemicals

Gastrointestinal Agents

Proton Pump Inhibitors

Bile Acids and Salts

Secretrol Capsules 80/80 once daily for 6 months

Secretrol

Prateek Sharma, M.D.

Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.

A majority of patients with Barrett's esophagus have poor distal esophageal pH control. Such patients frequently receive more than one dose of PPI per day in an attempt to improve esophageal pH control. Nocturnal pH control is notably difficult to achieve in many patients suffering from Barrett's esophagus. Recently, adverse effects have been associated with prolonged PPI use (defined as 1 year or longer). These include hypomagnesemia, bone fractures, Clostridium difficile induced diarrhea. High dose PPI as well as very high dose PPI usage (such as that used in hypersecretory conditions) has generally not been found to produce a different side effect or tolerability profile in humans. This study will evaluate the effects of Secretrol on tolerability, adverse effects and pH control of the distal esophagus and just below the squamocolumnar junction.

The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

Serum Gastrin 17 will be measured and compared to baseline.

Bile acids and bile salts can be affected by pH changes. The differential characterization of bile acid and bile salts will be performed at Baseline as compared to Day 30

Effexus Pharmaceutical

Rare Diseases

Stomach Neoplasms

Gastroesophageal Reflux

Bile Reflux

Gastrointestinal Neoplasms

Digestive System Neoplasms

Stomach Diseases

Biliary Tract Diseases

Duodenogastric Reflux

Stomach Cancer

Oculocerebral Syndrome With Hypopigmentation

patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results

patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results

patients with gastric cancer according to histopathological results

To explore the associations among bile acid profile, bile acid-microbiota cross-talk and the development of gastric cancer, so as to better prevent the occurrence and development of gastric cancer

This study is a case-control study. Patients, according to the pathological results, will be consecutively enrolled and divided into gastric cancer group, gastric precancerous lesions group, and chronic gastritis group. The serum and gastric juice bile acid profiles, gastric microbial composition of each group patients will be detected.

serum and gastric juice samples will not be retained; pathological tissue samples will be retained in Xijing Hospital

Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer

Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer: A Case-control Study

Investigators evaluate the corelation between the bile acid profile and gastric mucosa diseases according to the results of UPLC-MS/MS and pathological .

Investigators explore the cross-talk between bile acid and gastric microbiota according to the results of 16s rRNA sequencing

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus	NCT01905202	Barrett's Esoph...	Secretrol	18 Years -	Effexus Pharmaceutical
Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer	NCT04660058	Bile Reflux Gastric Cancer Precancerous Le...		18 Years - 75 Years	Xijing Hospital of Digestive Diseases
Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer	NCT04660058	Bile Reflux Gastric Cancer Precancerous Le...		18 Years - 75 Years	Xijing Hospital of Digestive Diseases

Spots Global Cancer Trial Database for bile acid

Every month we try and update this database with for bile acid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bile acid

Every month we try and update this database with for bile acid cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bile acid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.